Q-omics provides the consensus-scored RNASEK profile across patient tissues and cancer cell-line models. RNASEK expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNASEK is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RNASEK RNA expression shows 17,083 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where RNASEK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNASEK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNASEK survival associations across molecular data types. RNASEK RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNASEK RNA expression–survival associations across cancer types. High RNASEK expression shows unfavorable associations in KIRC, UVM, PRAD, LGG and GBM, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNASEK RNA expression.
This table summarizes RNASEK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RNASEK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNASEK shows lower tumor expression in COAD and higher tumor expression in KIRC, LIHC, KICH, THCA and CHOL. The KIRC box plot shows higher RNASEK RNA expression in tumor versus normal tissue (log2 FC = +0.447, t-test p < 0.001).
This table shows molecular features associated with RNASEK in patient tissues and cancer cell lines. In patient samples, RNASEK shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNASEK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
